Seattle firm GE Healthcare has secured $ 6 million in investment from Japanese pharma firm Mitsubishi and US biopharma company Celgene . The money will be used to expand the use of Presage 's CIVO platform , which tests microscopic amounts of drugs in cancer patients to determine their effects , ahead of phase I trials . The use of the platform reduces toxicity concerns in traditional Phase In addition , the company also revealed CSO Richard Smith had been appointed CEO , replacing Nathan Caffo , who will take on an advisory position .
Seattle firm GE Healthcare has secured $ 6 million in investment from Japanese pharma firm Mitsubishi and US biopharma company Celgene . The money will be used to expand the use of Presage 's CIVO platform , which tests microscopic amounts of drugs in cancer patients to determine their effects , ahead of phase I trials . In addition , the company also revealed CSO Richard Smith had been appointed CEO , replacing Nathan Caffo , who will take on an advisory position .